Pravastatin for preeclampsia: From animal to human
Pravastatin for preeclampsia: From animal to human
复制标题
DOI：
10.1111/jog.14295
复制
发表时间：
2020-06-02
影响因子：
1.6
通讯作者：
Fujii, Tomoyuki
中科院分区：
文献类型：
--
作者：
Kumasawa, Keiichi;Iriyama, Takayuki;Fujii, Tomoyuki
先兆子痫的特征是在怀孕20周后出现高血压和蛋白尿，如果继续下去，会威胁孕妇和胎儿的生命。尽管有许多研究，但到目前为止，先兆子痫的唯一基本治疗方法是终止妊娠，导致早产。此外，据报道，先兆子痫妇女在分娩后10年内有患心血管疾病的风险。因此，子痫前期的预防和治疗策略是必要的。最近，他汀类药物被报道可以促进血管内皮细胞的再生，而普伐他汀作为一种潜在的预防或治疗子痫前期的候选药物引起了人们的关注。普伐他汀已被证明在先兆子痫模型小鼠中具有预防作用，大量服用他汀类药物的孕妇的人体数据支持这些药物的安全性。此外，小型临床试验报告普伐他汀对先兆子痫有很强的预防或治疗作用，并有可能改善受这种情况影响的孕妇、胎儿和新生儿的预后。
Preeclampsia is characterized by the emergence of hypertension and proteinuria after 20 weeks of pregnancy, and it threatens both maternal and fetal lives if it proceeds unabated. Despite numerous studies, thus far the only fundamental therapy for preeclampsia is termination of pregnancy, leading to preterm birth. Furthermore, preeclamptic women are reported to be at risk for cardiovascular diseases for 10 years after delivery. Therefore, preventative and therapeutic strategies for preeclampsia are required. Recently, statins have been reported to improve the regeneration of vascular endothelium, and pravastatin has attracted attention as a potential preventative or therapeutic candidate for preeclampsia. Pravastatin has been demonstrated to have preventative effects in preeclampsia model mice, and a large volume of human data from pregnant women taking statins supports the safety of these drugs. Moreover, small clinical trials have reported that pravastatin has strong preventative or therapeutic effects on preeclampsia and it has the potential to improve the prognosis of pregnant women, fetuses and neonates affected by this condition.